Systemic Therapies for Pediatric Atopic Dermatitis

Sponsor

Rady Children’s Hospital, San Diego

Information provided by

Wynnis Tom, MD, Rady Children’s Hospital, San Diego

ClinicalTrials.gov Identifier

NCT01447381

Purpose

This study is designed to help understand the effect of systemic medications on children with eczema.

Eligibility

Ages Eligible for Study:  2-17 years

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Diagnosis of moderate, severe, or very severe atopic dermatitis, needing systemic therapy, severe or recalcitrant disease(at least two of: failure of multimodal therapy, significant impairment in life, inability to recieve/prior failure/need for more than one course of phototherapy, prior failure/need for more than one course of oral immunosuppresive medication), no medical condition preculding use of oral immunosuppresants, negative PPD within year, females of childbearing age must have a negative pregnancy test and use effective contraception.

Exclusion Criteria:

Female pregnant, nursing, planning pregnancy, concurrent enrollment in another trial with an investigational drug or device for atopic dermatitis, underlying medical problem that precludes participation, history of clinically significant drug or alcohol use in past year, considered unsuitable candidate by study investigator, active systemic infection that could worsen with atopic dermatitis treatment.

Locations

United States (CA, IL)

Principle Investigators

Wynnis Tom, MD, Rady Children’s Hospital and UC San Diego

http://clinicaltrials.gov/ct2/show/NCT01447381?term=eczema&rank=139